Literature DB >> 23465347

Flecainide or propafenone vs. vernakalant for conversion of recent-onset atrial fibrillation.

Diego Conde, Juan Pablo Costabel, Martin Aragon, Milagros Caro, Alejandra Ferro, Andres Klein, Marcelo Trivi, Alberto Giniger.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23465347     DOI： 10.1016/j.cjca.2013.01.002

Source DB:  PubMed          Journal:  Can J Cardiol        ISSN： 0828-282X            Impact factor:   5.223


× No keyword cloud information.
  4 in total

1.  Conversion of Recent-Onset Atrial Fibrillation: Which Drug is the Best?

Authors:  Diego Conde; Pablo Elissamburu; Nicolas Lalor; Leandro Rodriguez; Martin Aragon; Juan Pablo Costabel; Florencia Lambardi; Marcelo Trivi
Journal:  J Atr Fibrillation       Date:  2013-08-31

2.  Vernakalant and electrical cardioversion for AF - Safe and effective.

Authors:  Alexander Simon; Jan Niederdoeckl; Karin Janata; Alexander Oskar Spiel; Nikola Schuetz; Sebastian Schnaubelt; Harald Herkner; Filippo Cacioppo; Anton Norbert Laggner; Hans Domanovits
Journal:  Int J Cardiol Heart Vasc       Date:  2019-07-11

Review 3.  Safety and efficacy of vernakalant for acute cardioversion of atrial fibrillation: an update.

Authors:  Yukiomi Tsuji; Dobromir Dobrev
Journal:  Vasc Health Risk Manag       Date:  2013-04-23

4.  Vernakalant for Rapid Cardioversion of Recent-Onset Atrial Fibrillation: Results from the SPECTRUM Study.

Authors:  Samuel Lévy; Juha Hartikainen; Beate Ritz; Tord Juhlin; José Carbajosa-Dalmau; Hans Domanovits
Journal:  Cardiovasc Drugs Ther       Date:  2020-11-18       Impact factor: 3.727
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.